David Paterson at #ESCMIDGlobal2026 Highlights important issue of generic versus brand name meropenem – previous work has suggested chemical differences, harder to dissolve and even higher mortality with generic preparations
Great #UTI session just starting in Hall A2-1. D Neofytos talking now, Barbara Trautner @bwtrautner.bsky.social up next.
#ESCMIDGlobal2026
#IDSky #UTISky
Kai Huisman standing in front of his poster
So proud of my student Kaj Huisman of #Leiden, presenting his work showing an association between low beta-lactam blood levels and rapid Pseudomonas resistance development.
Poster P5302
#ESCMIDGlobal2026 #IDSky #TDM
Ilan, please count me in. Give me a task. Or ten. If starting an online ID #journalclub is what’s needed to resist a return to a platform promoting white supremacy and division amongst us for even more money for a few, then I count myself lucky. That’s not hard work at all.
#IDSky #ESCMIDGlobal2026
I think we should ask @germhuntermd.bsky.social 😊
😂
What’s scary is that meropenem today vs meropenem in 2018 has way too much mortality associated. David’s point about generic antibiotics & their poor performance really struck me. We don’t have great post-market quality control.
#ESCMIDGlobal2026 #IDSky
I hadn’t heard about throwing cats amongst pigeons. 😂 These trials are difficult and real life is so messy. 🙄
Late-breaking research at #ESCMIDGlobal2026
The SCOUT RCT in women with uncomplicated UTI challenges how we think about short-course antibiotics vs single-dose fosfomycin.
💊 Pragmatic, multicentre data
🌍 Real-world European settings
⚖️ Implications for stewardship
Can you tell how many ‘people’ at X are actually bots?
I love Bluesky because it’s still authentic communication amongst humans.
#IDsky
#ESCMIDGlobal2026
Why move people in that direction?
X algorithm will persist in amplifying extreme views, and platform is still owned by a proto fascist
Surely better to move folk remaining on X to bsky? Or for us all to get off our phones and talk to eachother!
There are also scientists interacting on LinkedIn
Superb session at #ESCMIDGlobal2026 on the PeterPen and ASTARTE trials
Important results, great discussion, thanks to @angelahuttner.bsky.social and friends
Big remaining evidence gap concerns optimal empiric (rather than follow on) therapy
ACORN study strategy with consent waiver may work
Erin McCreary at the podium with a slide showing her and Ryan Shields recording the first Breakpoints episode
Now @erinmccreary.bsky.social is speaking to a packed house on podcasting in infectious diseases, with photo of her and Ryan Shields recording the first #Breakpoints podcast in 2018 @sidpharm.bsky.social
#ESCMIDGlobal2026
From Carl Sagan via @neilstone.bsky.social
“When we are unable to distinguish between what feels good and what's true, we will side, almost without noticing, back into superstition
and darkness.”
#ESCMIDGlobal2026
#IDSky #clinmicro
Dr Neil Stone talking at a podium showing slides
Listening to @drneilstone.bsky.social talk about Twitter vs Bluesky in Arena 3:
Says don’t concede space in Twitter to anti-science influencers
#ESCMIDGlobal2026
#IDSky #clinmicro
Max Ernst Brühl 1891-1976 Paris Die Sirenen schlafen ein, wenn die Vernunft erwacht (Les sirènes s'endorment quand la raison se reveille), 1960 The Sirens Fall Asleep When Reason Awakes
Just a short U-Bahn ride from #ESCMIDglobal2026 is the Pinakothek der Moderne | Art
Max Ernst’s “The Sirens Fall Asleep When Reason Awakes” is a small slice of an amazing collection
#ESCMIDgreentravel
Oh no, I was talking trash! (Thought I counted 26, so what on earth else?) Thanks for setting me straight.
And that is my official corrigendum. 😊🇨🇭
A street banner in Zurich displaying the coats of arms of the 26 Swiss cantons
In the sky in #Zurich on the way to #ESCMIDGlobal2026, I found the coats of arms of Switzerland’s 26 cantons 🇨🇭
#ESCMIDgreentravel
📣 New #Communicable drops Mon, 20 April!
Thomas Tängdén, Erin McCreary, PharmD & Angela Huttner host Amy Legg & Rekha Pai for the first part in our new series on all things PK/PD! This episode introduces the topic broadly, defines essential concepts & discusses use cases in daily practice.🎙️
#IDSky
View of Lake Lémanv/Geneva with the mountains on the other side
The view from the train somewhere outside #Lausanne on the way to Munich
#ESCMIDGlobal2026
#ESCMIDgreentravel
the OG data centres 😂
📣Friedland on #host-directed therapies & #TB:
The study of physiology was central in the 20th century but now is something of a backwater, with attention focused on genetics & immunology to generate therapies. This must change..it impedes the development of effective HDTs.
ow.ly/EBig50YIFk0
#IDSky
📣 In vitro studies point to synergy between ertapenem and both cefazolin and nafcillin.
In this cohort of >50 patients with #MSSA #endocarditis receiving dual therapy, mortality & valve-replacement rates were lower than expected.
https://ow.ly/ZAfJ50YIFbR
#Staphaureus #IDSky #clinmicro
Come to #Microbio26 poster 094 to hear all about natural product antimocrobial discovery from @tosinorababa.bsky.social and me #MicroSky
Doctors are so cool ☺️
At #ESCMIDGlobal2026, tap water is drinking water! 💧
There will be water stations throughout the congress venue, but without disposable cups, so don't forget to pack your own water bottle to stay hydrated! 🚰
https://ow.ly/BOkk50YI4mL
#IDSky #clinmicro
@drandrekalil.bsky.social & Dr. Scherger co-authored an @annalsofim.bsky.social Journal Club on sepsis immunotherapy! #IDSky
www.acpjournals.org/doi/10.7326/...
Line graph showing the percentage distribution of Candida species from 2016 to 2024. Candida albicans is the most common species in most years, declining from about 36% to 32%. Candida glabrata increases overall, rising from about 25% in 2016 to a peak around 34% in 2024. Candida parapsilosis fluctuates between roughly 8% and 17% before declining to about 8% by 2024. Candida tropicalis and unspecified/other species remain relatively stable at lower levels (about 6–12%). Multiple-species infections decrease slightly over time. Candida auris is absent before 2022 and then increases to about 5% by 2023–2024.
Candida glabrata emerges as the most common cause of candidemia: analysis of a large hospital-based database, United States, 2016–2024
academic.oup.com/cid/advance-...
Jeremy Gold & colleagues at CDC Mycotic Diseases Branch, @jessicalittlemd.bsky.social and @drluiso.bsky.social
